ISRCTN53383289 https://doi.org/10.1186/ISRCTN53383289

Hypertension Evaluation Project III

Submission date 31/10/2007	**Recruitment status** No longer recruiting	[_] Prospectively registered [_] Protocol [_] Statistical analysis plan [X] Results [_] Individual participant data
Registration date 06/11/2007	**Overall study status** Completed	
Last Edited 31/12/2020	**Condition category** Circulatory System	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof Hans Wilhelm Hoepp

Contact details
Kerpener Str. 62
Cologne
Germany
50937
-
hw.hoepp@uni-koeln.de

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
3

Study information

Scientific Title

Hypertension Evaluation Project III

Acronym
HEP III

Study objectives
Innovative ways for dissemination of guidelines are superior to traditional ways.

Ethics approval required
Old ethics approval format

Ethics approval(s)
All participants took part voluntarily and the interventions were optional therefore ethics approval was not necessary.

Study design
Randomised controlled trial

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Not specified

Study type(s)
Quality of life

Participant information sheet

Health condition(s) or problem(s) studied
Hypertension

Interventions
1. Guideline in print
2. Interactive guideline
3. Expert seminars
4. Control group

The intervention groups were 3825 physicians for the expert seminars and always 1500 for the guideline in print, the interactive guideline and the control group. The medium follow-up time after intervention was approximately six months.

Intervention Type
Other

Phase
Not Specified

Primary outcome measure
Difference in guideline awareness between trained physicians and the control group.

Secondary outcome measures
Overall guideline awareness.

Overall study start date
01/01/2004

Completion date
31/03/2005

Eligibility

Key inclusion criteria
Participants of HEP I-trial: In the HEP-I trial we explored the guideline awareness of 24899 German physicians, including all internists, cardiologists and 22% of general practitioners in a nationwide survey. The data is already published (see http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=11677375)

Participant type(s)
Patient

Age group
Adult

Sex
Both

Target number of participants
8325

Total final enrolment
3825

Key exclusion criteria
See inclusion criteria.

Date of first enrolment
01/01/2004

Date of final enrolment
31/03/2005

Locations

Countries of recruitment
Germany

Study participating centre
Kerpener Str. 62
Cologne
Germany
50937

Sponsor information

Organisation
University of Cologne (Germany)

Sponsor details
Koeln Fortune Program
Faculty of Medicine
Kerpener Str. 62
Cologne
Germany
50937
-
t.hensler@uni-koeln.de

Sponsor type
University/education

Website
http://www.uni-koeln.de/index.e.html

ROR
https://ror.org/00rcxh774

Funder(s)

Funder type
University/education

Funder Name
University of Cologne (Germany) - Koeln Fortune Program, Faculty of Medicine

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	25/06/2008	31/12/2020	Yes	No